Digital Cervical and Cesarean Section
The Role of Digital Cervical Opening in Elective Cesarean Section
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71111
- Woman's Health Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All women scheduled for elective cesarean section will be approached.
- Women accepted to participate in the study participation after discussing the nature of the study.
Exclusion Criteria:
- Immuno-compromised women.
- Women suffering from any coagulation disorder or Blood disease.
- Blood transfusion during surgery or before it.
- History of wound infection or endometritis .
- Ante partum hemorrhage.
- History of long corticosteroid use.
- Women refuse to participate in the study.
- Suspected clinical evidence of infection.
- anemic women
- Multiple pregnancy
- Preterm births
- Rupture of membranes or chorioamnionitis
- Women who use antibiotics during the last 24 hours due to any infection but not prophylactic antibiotic during caesarian section
- Emergency caesarean section
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group A: cervical dilatation
patients who will have cervical dilatation during Caesarean section
|
Caesarean section will be done to deliver the baby
Cervical dilatation will be done by double gloves digital dilatation postpartum
|
|
Group A: non cervical dilatation
patients who will have not cervical dilatation during Caesarean section
|
Caesarean section will be done to deliver the baby
after delivery of the baby cervix will be remain closed
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The amount of postpartum blood loss (ml)
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- DCCS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.